Clinical trial registry record

A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 29, 2020.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03387566
Last registry update
July 29, 2020
Status
Completed
Phase
Phase 1
Sponsor
Huabo Biopharm Co., Ltd.
Enrollment
21
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
21
Population
ALL · 50 Years to 80 Years
Duration
2018-02-08 to 2020-03-23
Intervention
HB002.1M
Comparator
Not reported
Outcomes measured
Incidence of AE (Adverse Effect), DLT (Dose Limit Toxicity) and MTD (Maximum Tolerance Dose) — Up to 1 month after the…; T1/2 (Terminal phase half life) after single dose — 1 months; Cmax (maximum observed concentration) after single dose — 1 months; AUC (Area Under Concentration-Time Curve) after single dose — 1 months; Immunogenicity Evaluation after single dose — 2 months; Change in Best Corrected Visual Acuity (BCVA) from baseline — 1 month; Change in central retinal thickness from baseline by Optical Coherence Tomography (OCT) — 1 month; Change in Choroidal Neovascularization (CNV) lesion area from baseline according to fluorescein angiogram — 1 month; Change of VEGF(Vascular Endothelial Growth Factor A) from baseline — 1 month
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON